Background: Susceptibility to end-stage kidney disease (ESKD) among HIV-infected Americans of African ancestral heritage has been attributed to APOL1 genetic variation. We determined the frequency of the APOL1 G1 and G2 risk variants together with the prevalence of HIV-associated nephropathy (HIVAN) among individuals of Ethiopian ancestry to determine whether the kidney disease genetic risk is PanAfrican or restricted to West Africa, and can explain the previously reported low risk of HIVAN among Ethiopians. Methods: We studied a cohort of 338 HIV-infected individuals of Ethiopian ancestry treated in one Israeli and one Ethiopian center. We sought clinical evidence for HIVAN (serum creatinine >1.4 mg/dl or proteinuria >30 mg/dl in a spot urine sample). Genetic analyses included the genotyping of the APOL1 G1 and G2 variants, and a panel of 33 genomic ancestry-informative markers. Statistical analysis compared clinical and genetic indices for HIV-infected individuals of Ethiopian ancestry and overall Ethiopians to those reported for HIV-infected African-Americans, overall African-Americans, West Africans and non-Africans. Findings: Three (0.8%) of 338 HIV-infected patients of Ethiopian ancestry showed clinical criteria compatible with renal impairment. Two of these 3 patients also have severe poorly controlled diabetes mellitus. The third nondiabetic patient underwent renal biopsy which ruled out HIVAN. This absence of clinically apparent HIVAN was significantly different from that reported for African-Americans. The APOL1 G1 and G2 risk variants were found, respectively, in 0 and 2 (heterozygote state) of the 338 HIV-infected individuals. Global ancestry and the frequencies of the APOL1 G1 and G2 variants are not statistically different from their frequencies in the general Ethiopian population, but are significantly and dramatically lower than those observed among HIV-infected African-Americans, African-Americans and West Africans. Interpretation: The coinciding absence of HIVAN and the APOL1 risk variants among HIV-infected individuals of Ethiopian ancestry support a Western rather than Pan-African ancestry risk for ESKD, and can readily explain the lack of HIVAN among individuals of Ethiopian ancestry.

Keywords:
APOL1 genetic variation, HIV-associated nephropathy, Ancestry-informative markers, APOL1-associated nephropathies, Ethiopians
1.
USRDS: Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009.
2.
Kao WH, Klag MJ, Meoni LA, et al: MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008;40:1185–1192.
3.
Kopp JB, Smith MW, Nelson GW, et al: MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008;40:1175–1184.
4.
Behar DM, Rosset S, Tzur S, et al: African ancestry allelic variation at the MYH9 gene contributes to increased susceptibility to non-diabetic end-stage kidney disease in Hispanic Americans. Hum Mol Genet 2010;19:1816–1827.
5.
Shlush LI, Bercovici S, Wasser WG, et al: Admixture mapping of end stage kidney disease genetic susceptibility using estimated mutual information ancestry informative markers. BMC Med Genomics 2010;3:47.
6.
Genovese G, Friedman DJ, Ross MD, et al: Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010;329:841–845.
7.
Tzur S, Rosset S, Shemer R, et al: Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010;128:345–350.
8.
1000 Genome Project Consortium: A map of human genome variation from population-scale sequencing. Nature 2010;467:1061–1073.
9.
Rosset S, Tzur S, Behar DM, Wasser WG, Skorecki K: The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nat Rev Nephrol 2011;7:313–326.
10.
Eggers PW, Kimmel PL: Is there an epidemic of HIV Infection in the US ESRD program? J Am Soc Nephrol 2004;15:2477–2485.
11.
Kopp JB, Winkler C: HIV-associated nephropathy in African Americans. Kidney Int Suppl 2003:S43–S49.
12.
Rao TK: Human immunodeficiency virus (HIV) associated nephropathy. Annu Rev Med 1991;42:391–401.
13.
Katz IJ, Gerntholtz T, Naicker S: Africa and nephrology: the forgotten continent. Nephron Clin Pract 2010;117:c320–c327.
14.
Naicker S, Fabian J: Risk factors for the development of chronic kidney disease with HIV/AIDS. Clin Nephrol 2010;74(suppl 1): S51–S56.
15.
Behar DM, Shlush LI, Maor C, Lorber M, Skorecki K: Absence of HIV-associated nephropathy in Ethiopians. Am J Kidney Dis 2006;47:88–94.
16.
Petkov PM, Ding Y, Cassell MA, et al: An efficient SNP system for mouse genome scanning and elucidating strain relationships. Genome Res 2004;14:1806–1811.
17.
Johnson NI, Kotz S: Discrete Distributions. Boston, Houghton Mifflin, 1969.
18.
Tang H, Peng J, Wang P, Risch NJ: Estimation of individual admixture: analytical and study design considerations. Genet Epidemiol 2005;28:289–301.
19.
Thorisson GA, Smith AV, Krishnan L, Stein LD: The International HapMap Project Web site. Genome Res 2005;15:1592–1593.
20.
Wyatt CM, Winston JA, Malvestutto CD, et al: Chronic kidney disease in HIV infection: an urban epidemic. AIDS 2007;21:2101–2103.
21.
D’Agati V, Appel GB: HIV infection and the kidney. J Am Soc Nephrol 1997;8:138–152.
22.
Ahuja TS, Borucki M, Funtanilla M, Shahinian V, Hollander M, Rajaraman S: Is the prevalence of HIV-associated nephropathy decreasing? Am J Nephrol 1999;19:655–659.
23.
Wyatt CM, Morgello S, Katz-Malamed R, et al: The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy. Kidney Int 2009;75:428–434.
24.
Shahinian V, Rajaraman S, Borucki M, Grady J, Hollander WM, Ahuja TS: Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000;35:884–888.
25.
Behar DM, Yunusbayev B, Metspalu M, et al: The genome-wide structure of the Jewish people. Nature 2010;466:238–242.
26.
Kurimoto E: People of the River: Subsistence Economy of the Anywaa (Anuak) of Western Ethiopia. Essays in Northeast African Studies. Osaka, Senri Ethnological Studies, 1996, vol 43, pp 29–57.
27.
Bruggeman LA, Ross MD, Tanji N, et al: Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 2000;11:2079–2087.
28.
Marras D, Bruggeman LA, Gao F, et al: Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 2002;8:522–526.
29.
Winston JA, Bruggeman LA, Ross MD, et al: Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001;344:1979–1984.
30.
Bruggeman LA, Nelson PJ: Controversies in the pathogenesis of HIV-associated renal diseases. Nat Rev Nephrol 2009;5:574–581.
31.
D’Agati V, Suh JI, Carbone L, Cheng JT, Appel G: Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study. Kidney Int 1989;35:1358–1370.
32.
Choi AI, Rodriguez RA, Bacchetti P, Bertenthal D, Volberding PA, O’Hare AM: Racial differences in end-stage renal disease rates in HIV infection versus diabetes. J Am Soc Nephrol 2007;18:2968–2974.
33.
Freedman BI, Soucie JM, Stone SM, Pegram S: Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999;34:254–258.
34.
Szczech LA: Renal disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009;4:167–170.
35.
Li JZ, Absher DM, Tang H, et al: Worldwide human relationships inferred from genome-wide patterns of variation. Science 2008;319:1100–1104.
36.
Tishkoff SA, Reed FA, Friedlaender FR, et al: The genetic structure and history of Africans and African Americans. Science 2009;324:1035–1044.
37.
Bryc K, Auton A, Nelson MR, et al: Genome-wide patterns of population structure and admixture in West Africans and African Americans. Proc Natl Acad Sci USA 2010;107:786–791.
38.
Rogers DJ: Satellites, space, time and the African trypanosomiases. Adv Parasitol 2000;47:129–171.
39.
Simarro PP, Cecchi G, Paone M, et al: The atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 2010;9:57.
40.
Rotimi CN, Jorde LB: Ancestry and disease in the age of genomic medicine. N Engl J Med 2010;363:1551–1558.
41.
Lucas GM, Mehta SH, Atta MG, et al: End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004. AIDS 2007;21:2435–2443.
42.
Krawczyk CS, Holmberg SD, Moorman AC, Gardner LI, McGwin G, Jr: Factors associated with chronic renal failure in HIV-infected ambulatory patients. AIDS 2004;18:2171–2178.
43.
El-Sadr WM, Lundgren JD, Neaton JD, et al: CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283–2296.
44.
Kalayjian RC: The treatment of HIV-associated nephropathy. Adv Chronic Kidney Dis 201017:59–71.
45.
Papeta N, Sterken R, Kiryluk K, Kalyesubula R, Gharavi AG: The molecular pathogenesis of HIV-1 associated nephropathy: recent advances. J Mol Med 2011;89:429–436.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.